PRRT2 and melanoma: Taken all together, our results have shown that the PKC inhibitors; i.e. Gö6976 and Gö6983, differentially affect the reversion of E- to N-cadherin switch and metastatic phenotype in aggressive melanoma cells (Figs. 1, 2, 3, 4, 5 and 6).